INHALE WP3: Antibiotic Prescribing Guidance for use with FilmArray Result

CONSIDERATIONS

- 1. Adjust dosages for renal function as per Manufacturer's SPC
- 2. For patients already on antimicrobial treatment for infections necessitating specific regimens e.g. infective endocarditis/ meningitis please discuss with Microbiology how best to adapt their treatment for organism(s) found by FilmArray.
- 3. Pregnant and paediatric patients: Please note general recommendations regarding use of fluoroquinolones, tetracyclines, colistin, temocillin and ceftazidime-avibactam. See https://www.medicines.org.uk/emc/ for specifics.
- 4. Please be aware that Biofire FilmArray does not detect *Stenotrophomonas maltophilia*. If *S. maltophilia* infection is suspected please adjust therapy accordingly in at risk populations.

Кеу

No known allergy to antibiotics Mild allergy to β -lactams i.e. rash Severe allergy to β -lactams, i.e. anaphylaxis Not applicable

Table 1. To be used when $\overline{\mathsf{ONE}}$ Organism is Detected by FilmArray

First Whatorganism was found & it the patient allergic to β-lactams		Second If NO resistance genes found, this is the advised R _x	Third If resistance genes found, this is your advised R _x Resistance Marker					
		None	CTX-M	KPC or OXA-48	IMP, NDM or VIM	<i>mecA</i> or <i>mecC</i>		
	No organisms found	Antibiotics should be stopped unless there is clear evidence for probable or proven bacterial infection severe enough to warrant them						
	Any virus	Co-amoxiclav +antiviral if appropriate Cefuroxime +antiviral if appropriate Levofloxacin + antiviral if appropriate						

INHALE Antibiotic Prescribing Guidelines v2.0 08May2019 MASTER [This document is intended to be made site specific and this will be indicated by the Trust name in the footer, followed by an additional version number and draft or final to indicate whether it is approved by the trial team] © 2018 University College Hospitals NHS Foundation Trust Page 2 of 6

First What organism was found & it the patient allergic to β-lactams		Second If NO resistance genes found, this is the advised R _x	Third If resistance genes found, this is your advised R _x					
		None	CTX-M	KPC or OXA-48	IMP, NDM or VIM	<i>mecA</i> or <i>mecC</i>		
	Any virus + 1 or more bacteria	Treat as indicated for bacterial infection and add antiviral treatment where appropriate						
		Meropenem ¹						
		Meropenem ¹						
	A. baumannii	Colistin alone or in						
		appropriate						
Organism	E. aerogenes, E. cloacae, E. coli, K. pneumoniae or K. oxytoca	Temocillin (2g TDS)	Temocillin (2g TDS)	Ceftazidime-avibactam ³	Colistin alone or in combination ² if clinically appropriate			
		Ceftriaxone (<i>Klebsiella</i> spp. & <i>E. coli</i>) OR Meropenem for <i>Enterobacter</i> spp.	Meropenem	Ceftazidime-avibactam ³	Colistin alone or in combination ² if clinically appropriate			
		Le	Levofloxacin or Ciprofloxacin	Colistin alone or in combination ² if clinically appropriate	Colistin alone or in combination ² if clinically appropriate	Colistin alone or in combination ² if clinically appropriate		
	Proteus spp. or S. marcescens	Piperacillin-tazobactam for Serratia sp. OR Temocillin 2g TDS for Proteus sp.	Temocillin 2g TDS for Proteus sp. OR Meropenem for Serratia sp.	Ceftazidime-avibactam ³	Fosfomycin ⁴			
		Ceftriaxone	Meropenem	Ceftazidime-avibactam ³	Fosfomycin ⁴			
		Fosfomycin ⁴	Fosfomycin ⁴	Fosfomycin ⁴	Fosfomycin ⁴			
		Co-amoxiclav						
	II influenzae	Ceturoxime						
	H. Influenzae	or Ciproflovacin						
		or cipronoxaciii						

INHALE Antibiotic Prescribing Guidelines v2.0 08May2019 MASTER [This document is intended to be made site specific and this will be indicated by the Trust name in the footer, followed by an additional version number and draft or final to indicate whether it is approved by the trial team] © 2018 University College Hospitals NHS Foundation Trust Page 3 of 6

	M. catarrhalis	Co-amoxiclav Cefuroxime Doxycycline OR Levofloxacin or Ciprofloxacin				
		Ceftazidime (2g TDS)	Meropenem	Ceftazidime-avibactam ³	Colistin alone or in combination ² if clinically appropriate	
	P. aeruginosa	Ceftazidime (2g TDS)	Meropenem	Ceftazidime-avibactam ³	Colistin alone or in combination ² if clinically appropriate	
_		Colistin alone or in combination ² if clinically appropriate	Colistin alone or in combination ² if clinically appropriate	Colistin alone or in combination ² if clinically appropriate	Colistin alone or in combination ² if clinically appropriate	
	S. aureus	Flucloxacillin ⁵				Glycopeptide ⁶ or Linezolid
		Cefuroxime				Glycopeptide ⁶ or Linezolid
		Glycopeptide ⁶ or Linezolid				Glycopeptide ⁶ or Linezolid
	S. agalactiae, S.	Amoxicillin				
	pneumoniae or S.	Cefuroxime				
	pyogenes	Glycopeptide ⁶ or Linezolid				
		Macrolide ⁷ OR Levofloxacin or				
	C. pneumoniae, L.	Ciprofloxacin				
	pneumophila, M.	Ciprofloxacin				
	pneumoniae	Macrolide ⁷ OR Levofloxacin or				
		Ciprofloxacin				

Footnotes

- 1. In units with high rates of carbapenem resistance, or if experiencing outbreak of carbapenem-resistant *A. baumannii* follow same recommendations as for treatment in case of allergy
- 2. Colistin can be combined with an appropriate second antimicrobial such as rifampicin or tigecycline. The choice is left open according to local preference.
- 3. Please discuss with microbiologist before prescribing
- 4. Consider adding colistin as metallo β-lactamase likely to be present in undetected host organism
- 5. If clinical picture suggests PVL-positive *S. aureus* consider ordering PVL test and switching to linezolid
- 6. Vancomycin or teicoplanin
- 7. Clarithromycin or azithromycin

INHALE Antibiotic Prescribing Guidelines v2.0 08May2019 MASTER [This document is intended to be made site specific and this will be indicated by the Trust name in the footer, followed by an additional version number and draft or final to indicate whether it is approved by the trial team] © 2018 University College Hospitals NHS Foundation Trust Page 4 of 6

Кеу

No known allergy to antibiotics Mild allergy to β -lactams i.e. rash Severe allergy to β -lactams, i.e. anaphylaxis Not applicable

Table 2. Recommended treatment for combination of **TWO** or more organisms are detected by FilmArray

PLEASE READ THIS TABLE FROM LEFT TO RIGHT; Coloured boxes refer to allergy status as in Table 1. **Key**: + organism present, - organism absent, ± either present or absent

First, What combination of bacteria have been found?							Third: if	resista	ince genes f	found
A. baumannii	Enterobacterales: E. aerogenes, E. cloacae, E. coli, K. pneumoniae ,K. oxytoca, Proteus sp., S. marcescens	P. aeruginosa	H. influenzae/M. catarrhalis	S. aureus	S. agalactiae, S. pneumoniae or S. pyogenes	Therapy if no resistance genes	<i>mecA/C</i> found	CTX-M found	C. pneumoniae, L. pneumophila OR M. pneumoniae	Carbapen- emase found
	Do	es the mixtur	e include Acino	etobacter? If Y	'ES ; stay with	this block; if	NO, go to nex	t block		
+	Any one or more second organism found						Add Glycopeptide ¹⁰ OR Linezolid	-	Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	Discuss with Micro- biology
+	± Any one or more second organism found					Meropenem ⁸	Add Glycopeptide ¹⁰ OR Linezolid	-	Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	Discuss with Micro- biology
+	Add Levofloxacin or Ciprofloxacin ⁹	Add Levofloxacin or Ciprofloxacin ⁹	Add Levofloxacin or Ciprofloxacin ⁹	Add Glycopeptide ¹⁰ OR Linezolid	Add Glycopeptide ¹⁰ OR Linezolid	Colistin Combination	Add Glycopeptide ¹⁰ OR Linezolid	Discuss with Micro- biology	Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	Discuss with Micro- biology

INHALE Antibiotic Prescribing Guidelines v2.0 08May2019 MASTER [This document is intended to be made site specific and this will be indicated by the Trust name in the footer, followed by an additional version number and draft or final to indicate whether it is approved by the trial team] © 2018 University College Hospitals NHS Foundation Trust Page 5 of 6

Fir	<mark>st,</mark> What com	bination of	f bacteria ha	ave been fo	und?	Second:	Third: if	resista	ince genes f	found
A. baumannii	E. aerogenes, E. cloacae, E. coli, K. pneumoniae, K. oxytoca, Proteus sp., S. marcescens	P. aeruginosa	H. influenzae/M. catarrhalis	S. aureus	S. agalactiae, S. pneumoniae or S. pyogenes	Therapy if no resistance genes	<i>mecA/C</i> found	CTX-M found	C. pneumoniae, L. pneumophila OR M. pneumoniae	Carbapen- emase found
		If NO Acir	<i>etobacter</i> : bu	t <u>></u> 1 Pseudom	onas/Enterob	acteriales fou	und start here	_		_
- + (at least one)		±	±	±	Piperacillin/Ta zobactam	Add Glycopeptide ¹⁰ OR Linezolid	Escalate to Meropen em	Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	Discuss with Micro- biology	
-	+ (at least one)		±	±	±	Meropenem	Add Glycopeptide ¹⁰ OR Linezolid	-	Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	Discuss with Micro- biology
-	Add Levofloxacin or Ciprofloxacin ⁹	Add Levofloxacin or Ciprofloxacin ⁹	Add Levofloxacin or Ciprofloxacin ⁹	Add Glycopeptide ¹⁰ OR Linezolid	Add Glycopeptide ¹⁰ OR Linezolid	Colistin Combination as indicated	Add Glycopeptide ¹⁰ OR Linezolid	Discuss with Micro- biology	Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	Discuss with Micro- biology
	If NO Acinetobacter NO Pseudomonas & NO Enterobacteriaceae start here									
None of these			Aı	ny 2 or more of the	se	Co-amoxiclav	Add Glycopeptide ¹⁰ OR Linezolid		Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	
None of these			Any 2 or more of these		Levofloxacin	Add Glycopeptide ¹⁰ OR Linezolid		Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin		
None of these			A	ny 2 or more of the	ese	Levofloxacin	Add Glycopeptide ¹⁰ OR Linezolid		Add Macrolide ¹¹ OR Levofloxacin or Ciprofloxacin	

Footnotes

8. Add colistin in in areas of high carbapenem-resistance among *A. baumanii*.

9. Consider adding tigecycline of fosfomycin if fluoroquinolone resistance locally prevalent

10. Vancomycin or teicoplanin

11. Clarithromycin or azithromycin

INHALE Antibiotic Prescribing Guidelines v2.0 08May2019 MASTER [This document is intended to be made site specific and this will be indicated by the Trust name in the footer, followed by an additional version number and draft or final to indicate whether it is approved by the trial team] © 2018 University College Hospitals NHS Foundation Trust Page 6 of 6